Becton, Dickinson and Company

NYSE:BDX

Medical - Instruments & Supplies

Healthcare
$216.08 +1.67%

+$2.36 today

Market cap
$58.86B
Beta
0.28
P/E (TTM)
35.5
EPS (TTM)
$4.06
Dividend yield
2.60%
52W Low $127.59High $187.35

Volume 1.32M

Average 2.76M

BDX Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Becton, Dickinson and CompanyNYSE: BDX

Depreciation & Amortization · Q4 FY2026 · quarter ended Sep 2026

Depreciation & amortization declines year over year

Q4 FY2026 depreciation & amortization of $541M fell 14.0% year over year, behind the -4.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 3.9% from the prior quarter. Over 3 fiscal years it compounded at -0.7% a year.

Context

  • Depreciation & amortization amounted to 11.5% of revenue in FY2026, up 0.2 pp from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.
  • FY2026 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -14.0% toward the trailing-twelve-month pace of -4.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$541M-3.9% QoQ
Last fiscal yearSep 2026
$2.24B-9.1% YoY
LTMSep 2026
$2.24B-4.2% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-14.0%——
1 year-9.1%——
3-year CAGR-0.7%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2026
2.24B USD
Year-over-year change
-9.1%
4-year CAGR
+0.1%

Depreciation & Amortization vs competitors

How BDX compares with its peers on the latest reported figures

  • BDX's LTM Sep 2026 depreciation & amortization of $2.24B is the 3rd largest of the 11 companies compared; the peer median is $193.14M.
  • Its year-over-year change of -4.2% is the 7th highest of 11, against a peer median of -2.4%.
  • Depreciation & amortization amounts to 11.1% of revenue for BDX, versus a peer median of 7.1%.
BDX Competitors Peer median
Depreciation & Amortization for BDX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABTAbbott LaboratoriesLTM Jun 2026$3.33B +5.9%-1.6%7.1%
MDTMedtronic plcLTM Jul 2026$2.85B -3.4%+3.1%7.6%
BDXBecton, Dickinson and CompanyLTM Sep 2026$2.24B -4.2%-0.7%11.1%
BAXBaxter International Inc.LTM Jun 2026$953M -5.0%-2.9%8.3%
SOLVSolventum CorporationLTM Jun 2026$506M -5.2%-5.4%6.1%
ICUIICU Medical, Inc.LTM Jun 2026$204.78M -1.5%-5.1%9.5%
TFXTeleflex IncorporatedLTM Jun 2026$181.49M -33.6%-8.3%7.0%
WSTWest Pharmaceutical Services, Inc.LTM Jun 2026$180.8M +11.4%+12.4%5.4%
MMSIMerit Medical Systems, Inc.LTM Sep 2026$136.48M +3.5%+13.5%8.5%
EMBCEmbecta Corp.LTM Mar 2026$40.2M +14.2%+8.7%3.9%
BLFSBioLife Solutions, Inc.LTM Mar 2026$4M -48.5%-34.2%4.0%
Peer median (excluding BDX) $193.14M-2.4%-2.2%7.1%

Competitors are the stored peer set for BDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
FY2026
Sep 2026
Net Income1.78B1.53B1.71B1.68B1.15B
Depreciation & Amortization2.23B2.29B2.29B2.46B2.24B
Deferred Income Tax(120M)(622M)(211M)(474M)0
Stock-Based Compensation233M259M247M258M0
Change in Working Capital(1.39B)(630M)293M(800M)(50M)
Accounts Receivables32M(290M)(453M)71M0
Inventory(631M)(15M)98M(410M)0
Accounts Payables(473M)(517M)625M(185M)0
Other Working Capital(322M)192M23M(276M)(50M)
Other Non-Cash Items(94M)164M(522M)306M272M
Operating Cash Flow2.63B2.99B3.8B3.43B3.61B
Capital Expenditures(973M)(874M)(725M)(760M)(672M)
Acquisitions (Net)(2.07B)540M(3.92B)0(22M)
Purchases of Investments00(421M)00
Sales of Investments000422M20M
Other Investing Activities(188M)(382M)(444M)(480M)(336M)
Investing Cash Flow(3.23B)(716M)(5.51B)(818M)(1.01B)
Debt Repayment(78M)(722M)3.78B(1.33B)(2.41B)
Common Stock Issued00000
Common Stock Repurchased(500M)0(500M)(1B)(2.43B)
Dividends Paid(1.08B)(1.11B)(1.1B)(1.2B)(1.16B)
Other Financing Activities1.07B(121M)(88M)(87M)3.84B
Financing Cash Flow(591M)(1.96B)2.09B(3.62B)(2.16B)
Effect of Forex Changes(45M)5M4M07M
Net Change in Cash(1.23B)322M375M(1.01B)233M
Free Cash Flow1.66B2.12B3.07B2.67B2.93B

Becton, Dickinson and Company

NYSE:BDX

Intrinsic Alpha fair value

Locked

Current Price

$216.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.